TIDMHIK
RNS Number : 8971D
Hikma Pharmaceuticals Plc
07 March 2022
Hikma Pharmaceuticals PLC - EIP B Vesting
LONDON, 7 March 2022: Hikma Pharmaceuticals PLC (LSE: HIK)
(NasdaqDubai: HIK) ("Hikma") (LEI: 549300BNS685UXH4JI75) announces
that the following Persons Discharging Managerial Responsibility
("PDMR") have received shares as a result of the vesting of their
conditional share awards which were granted on 27 February 2020
under the 2014 Executive Incentive Plan ("EIP") Element B. The
vesting process was completed on 4 March 2022.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities
Said Darwazah
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Said Darwazah
2 Reason for the notification
a) Position/status Executive Chairman
b) Initial notification Initial notification
/Amendment
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
a) Description of Description: Ordinary shares of 10 pence each
the financial (Shares)
instrument, type ID Code: GB00B0LCW083
of instrument
and identification
code
b) Nature of the Shares acquired from the vesting of conditional
transaction awards on
28 February 2022 under the EIP Element B. All
Shares were retained.
c) Price(s) and Price(s): GBPnil
volume(s) Volume(s): 47,169
d) Aggregated information
* Volume
47,169
GBP0.00
* Price GBP0.00
* Total
e) Date of the transaction 4 March 2022
f) Place of the London Stock Exchange (XLON)
transaction
Siggi Olafsson
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Sigurdur Olafsson
2 Reason for the notification
a) Position/status Chief Executive Officer
b) Initial notification Initial notification
/Amendment
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
a) Description of Description: Ordinary shares of 10 pence each
the financial (Shares)
instrument, type ID Code: GB00B0LCW083
of instrument
and identification
code
b) Nature of the Shares acquired from the vesting of conditional
transaction awards on
28 February 2022 under the EIP Element B. 20,298
Shares were sold to cover tax and the remainder
were retained.
c) Price(s) and Price(s): GBPnil
volume(s) Volume(s): 32,850
Price(s): GBP19.57
Volume(s): 20,298
d) Aggregated information
* Volume
53,148
GBP19.57
* Price GBP397,231.86
* Total
e) Date of the transaction 4 March 2022
f) Place of the London Stock Exchange (XLON)
transaction
Mazen Darwazah
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Mazen Darwazah
2 Reason for the notification
a) Position/status Executive Vice Chairman
b) Initial notification Initial notification
/Amendment
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
a) Description of Description: Ordinary shares of 10 pence each
the financial (Shares)
instrument, type ID Code: GB00B0LCW083
of instrument
and identification
code
b) Nature of the Shares acquired from the vesting of conditional
transaction awards on
28 February 2022 under the EIP Element B. All
Shares were retained.
c) Price(s) and Price(s): GBPnil
volume(s) Volume(s): 32,993
d) Aggregated information
* Volume
32,993
GBP0.00
* Price GBP0.00
Total
e) Date of the transaction 4 March 2022
f) Place of the London Stock Exchange (XLON)
transaction
Riad Mishlawi
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Riad Mishlawi
2 Reason for the notification
a) Position/status PDMR
b) Initial notification Initial notification
/Amendment
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
a) Description of Description: Ordinary shares of 10 pence each
the financial (Shares)
instrument, type ID Code: GB00B0LCW083
of instrument
and identification
code
b) Nature of the Shares acquired from the vesting of conditional
transaction awards on
28 February 2022 under the EIP Element B. All
Shares were retained.
c) Price(s) and Price(s): GBPnil
volume(s) Volume(s): 27,086
d) Aggregated information
* Volume
27,086
GBP0.00
* Price GBP0.00
* Total
e) Date of the transaction 4 March 2022
f) Place of the London Stock Exchange (XLON)
transaction
Majda Labadi
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Majda Labadi
2 Reason for the notification
a) Position/status PDMR
b) Initial notification Initial notification
/Amendment
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
a) Description of Description: Ordinary shares of 10 pence each
the financial (Shares)
instrument, type ID Code: GB00B0LCW083
of instrument
and identification
code
b) Nature of the Shares acquired from the vesting of conditional
transaction awards on
28 February 2022 under the EIP Element B. All
Shares were retained.
c) Price(s) and Price(s): GBPnil
volume(s) Volume(s): 14,211
d) Aggregated information
* Volume
14,211
GBP0.00
* Price GBP0.00
* Total
e) Date of the transaction 4 March 2022
f) Place of the London Stock Exchange (XLON)
transaction
Bassam Kanaan
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Bassam Kanaan
2 Reason for the notification
a) Position/status PDMR
b) Initial notification Initial notification
/Amendment
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
a) Description of Description: Ordinary shares of 10 pence each
the financial (Shares)
instrument, type ID Code: GB00B0LCW083
of instrument
and identification
code
b) Nature of the Shares acquired from the vesting of conditional
transaction awards on
28 February 2022 under the EIP Element B. All
Shares were retained.
c) Price(s) and Price(s): GBPnil
volume(s) Volume(s): 22,610
d) Aggregated information
* Volume
22,610
GBP0.00
* Price GBP0.00
* Total
e) Date of the transaction 4 March 2022
f) Place of the London Stock Exchange (XLON)
transaction
Khalid Nabilsi
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Khalid Nabilsi
2 Reason for the notification
a) Position/status PDMR
b) Initial notification Initial notification
/Amendment
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
a) Description of Description: Ordinary shares of 10 pence each
the financial (Shares)
instrument, type ID Code: GB00B0LCW083
of instrument
and identification
code
b) Nature of the Shares acquired from the vesting of conditional
transaction awards on
28 February 2022 under the EIP Element B. All
Shares were retained.
c) Price(s) and Price(s): GBPnil
volume(s) Volume(s): 22,709
d) Aggregated information
* Volume
22,709
GBP0.00
* Price GBP0.00
* Total
e) Date of the transaction 4 March 2022
f) Place of the London Stock Exchange (XLON)
transaction
Brian Hoffmann
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Brian Hoffmann
2 Reason for the notification
a) Position/status PDMR
b) Initial notification Initial notification
/Amendment
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
a) Description of Description: Ordinary shares of 10 pence each
the financial (Shares)
instrument, type ID Code: GB00B0LCW083
of instrument
and identification
code
b) Nature of the Shares acquired from the vesting of conditional
transaction awards on
28 February 2022 under the EIP Element B. 5,516
Shares were sold to cover tax and the remainder
were retained.
c) Price(s) and Price(s): GBPnil
volume(s) Volume(s): 8,925
Price(s): GBP19.57
Volume(s): 5,516
d) Aggregated information
* Volume
14,441
GBP19.57
* Price GBP107,948.12
* Total
e) Date of the transaction 4 March 2022
f) Place of the London Stock Exchange (XLON)
transaction
Susan Ringdal
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Susan Ringdal
2 Reason for the notification
a) Position/status PDMR
b) Initial notification Initial notification
/Amendment
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
a) Description of Description: Ordinary shares of 10 pence each
the financial (Shares)
instrument, type ID Code: GB00B0LCW083
of instrument
and identification
code
b) Nature of the Shares acquired from the vesting of conditional
transaction awards on
28 February 2022 under the EIP Element B. 5,550
Shares were sold to cover tax and the remainder
were retained.
c) Price(s) and Price(s): GBPnil
volume(s) Volume(s): 6,199
Price(s): GBP19.57
Volume(s): 5,550
d) Aggregated information
* Volume
11,749
GBP19.57
* Price GBP108,613.50
* Total
e) Date of the transaction 4 March 2022
f) Place of the London Stock Exchange (XLON)
transaction
Henriette Nielsen
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Henriette Nielsen
2 Reason for the notification
a) Position/status PDMR
b) Initial notification Initial notification
/Amendment
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
a) Description of Description: Ordinary shares of 10 pence each
the financial (Shares)
instrument, type ID Code: GB00B0LCW083
of instrument
and identification
code
b) Nature of the Shares acquired from the vesting of conditional
transaction awards on
28 February 2022 under the EIP Element B. 5,972
Shares were sold to cover tax and the remainder
were retained.
c) Price(s) and Price(s): GBPnil
volume(s) Volume(s): 9,663
Price(s): GBP19.57
Volume(s): 5,972
d) Aggregated information
* Volume
15,635
GBP19.57
* Price GBP116,872.04
* Total
e) Date of the transaction 4 March 2022
f) Place of the London Stock Exchange (XLON)
transaction
Shahin Fesharaki
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Shahin Fesharaki
2 Reason for the notification
a) Position/status PDMR
b) Initial notification Initial notification
/Amendment
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
a) Description of Description: Ordinary shares of 10 pence each
the financial (Shares)
instrument, type ID Code: GB00B0LCW083
of instrument
and identification
code
b) Nature of the Shares acquired from the vesting of conditional
transaction awards on
28 February 2022 under the EIP Element B. 2,961
Shares were sold to cover tax and the remainder
were retained.
c) Price(s) and Price(s): GBPnil
volume(s) Volume(s): 4,791
Price(s): GBP19.57
Volume(s): 2,961
d) Aggregated information
* Volume
7,752
GBP19.57
* Price GBP57,946.77
* Total
e) Date of the transaction 4 March 2022
f) Place of the London Stock Exchange (XLON)
transaction
Hussein Arkhagha
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Hussein Arkhagha
2 Reason for the notification
a) Position/status PDMR
b) Initial notification Initial notification
/Amendment
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
a) Description of Description: Ordinary shares of 10 pence each
the financial (Shares)
instrument, type ID Code: GB00B0LCW083
of instrument
and identification
code
b) Nature of the Shares acquired from the vesting of conditional
transaction awards on
28 February 2022 under the EIP Element B. All
Shares were retained.
c) Price(s) and Price(s): GBPnil
volume(s) Volume(s): 11,308
d) Aggregated information
* Volume
11,308
GBP0.00
* Price GBP0.00
* Total
e) Date of the transaction 4 March 2022
f) Place of the London Stock Exchange (XLON)
transaction
Peter Speirs
Company Secretary, responsible for releasing this
announcement
+44 (0) 20 7399 2760
7 March 2022
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHBXGDXUXGDGDR
(END) Dow Jones Newswires
March 07, 2022 08:36 ET (13:36 GMT)
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024